These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 12663685)

  • 1. Increased endothelin-induced Ca2+ signaling, tyrosine phosphorylation, and coronary artery disease in diabetic dyslipidemic Swine are prevented by atorvastatin.
    Lee DL; Wamhoff BR; Katwa LC; Reddy HK; Voelker DJ; Dixon JL; Sturek M
    J Pharmacol Exp Ther; 2003 Jul; 306(1):132-40. PubMed ID: 12663685
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Atorvastatin treatment prevents alterations in coronary smooth muscle nuclear Ca2+ signaling in diabetic dyslipidemia.
    Wamhoff BR; Dixon JL; Sturek M
    J Vasc Res; 2002; 39(3):208-20. PubMed ID: 12097819
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hyperglycemia-induced insulin resistance in diabetic dyslipidemic Yucatan swine.
    Otis CR; Wamhoff BR; Sturek M
    Comp Med; 2003 Feb; 53(1):53-64. PubMed ID: 12625507
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of ezetimibe added on to atorvastatin (20 mg) versus uptitration of atorvastatin (to 40 mg) in hypercholesterolemic patients at moderately high risk for coronary heart disease.
    Conard SE; Bays HE; Leiter LA; Bird SR; Rubino J; Lowe RS; Tomassini JE; Tershakovec AM
    Am J Cardiol; 2008 Dec; 102(11):1489-94. PubMed ID: 19026302
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of atorvastatin on intracellular calcium uptake in coronary smooth muscle cells from diabetic pigs fed an atherogenic diet.
    Hill BJ; Dixon JL; Sturek M
    Atherosclerosis; 2001 Nov; 159(1):117-24. PubMed ID: 11689213
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effects of different doses of atorvastatin on plasma endothelin-1 levels in type 2 diabetic patients with dyslipidemia.
    Lam HC; Chu CH; Wei MC; Keng HM; Lu CC; Sun CC; Lee JK; Chuang MJ; Wang MC; Tai MH
    Exp Biol Med (Maywood); 2006 Jun; 231(6):1010-5. PubMed ID: 16741040
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Statin therapy helps to control blood pressure levels in hypertensive dyslipidemic patients.
    Kanbay M; Yildirir A; Bozbas H; Ulus T; Bilgi M; Muderrisoglu H; Akcay A; Ozdemir FN
    Ren Fail; 2005; 27(3):297-303. PubMed ID: 15957546
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of ezetimibe added on to atorvastatin (40 mg) compared with uptitration of atorvastatin (to 80 mg) in hypercholesterolemic patients at high risk of coronary heart disease.
    Leiter LA; Bays H; Conard S; Bird S; Rubino J; Hanson ME; Tomassini JE; Tershakovec AM
    Am J Cardiol; 2008 Dec; 102(11):1495-501. PubMed ID: 19026303
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The influence of low-dose atorvastatin on lipid levels and endothelial vascular function in patients with significant coronary artery stenosis.
    Kuryata OV; Yegorova YV
    Kardiol Pol; 2006 Jan; 64(1):44-8; discussion 49-50. PubMed ID: 16444629
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High-dose atorvastatin improves hypercholesterolemic coronary endothelial dysfunction without improving the angiogenic response.
    Boodhwani M; Nakai Y; Voisine P; Feng J; Li J; Mieno S; Ramlawi B; Bianchi C; Laham R; Sellke FW
    Circulation; 2006 Jul; 114(1 Suppl):I402-8. PubMed ID: 16820608
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased atherosclerosis in diabetic dyslipidemic swine: protection by atorvastatin involves decreased VLDL triglycerides but minimal effects on the lipoprotein profile.
    Dixon JL; Shen S; Vuchetich JP; Wysocka E; Sun GY; Sturek M
    J Lipid Res; 2002 Oct; 43(10):1618-29. PubMed ID: 12364546
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of atorvastatin versus fenofibrate in reaching lipid targets and influencing biomarkers of endothelial damage in patients with familial combined hyperlipidemia.
    Arca M; Montali A; Pigna G; Antonini R; Antonini TM; Luigi P; Fraioli A; Mastrantoni M; Maddaloni M; Letizia C
    Metabolism; 2007 Nov; 56(11):1534-41. PubMed ID: 17950105
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib as monotherapy and coadministered with atorvastatin in dyslipidemic patients.
    Bloomfield D; Carlson GL; Sapre A; Tribble D; McKenney JM; Littlejohn TW; Sisk CM; Mitchel Y; Pasternak RC
    Am Heart J; 2009 Feb; 157(2):352-360.e2. PubMed ID: 19185645
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Atorvastatin or fenofibrate on post-prandial lipaemia in type 2 diabetic patients with hyperlipidaemia.
    Iovine C; Lilli S; Gentile A; Patti L; Di Marino L; Cipriano P; Riccardi G; Rivellese AA
    Eur J Clin Invest; 2006 Aug; 36(8):560-5. PubMed ID: 16893378
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined use of extended-release niacin and atorvastatin: safety and effects on lipid modification.
    Sang ZC; Wang F; Zhou Q; Li YH; Li YG; Wang HP; Chen SY
    Chin Med J (Engl); 2009 Jul; 122(14):1615-20. PubMed ID: 19719960
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Altered functional coupling of coronary K+ channels in diabetic dyslipidemic pigs is prevented by exercise.
    Mokelke EA; Hu Q; Song M; Toro L; Reddy HK; Sturek M
    J Appl Physiol (1985); 2003 Sep; 95(3):1179-93. PubMed ID: 12777409
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Achieving lipoprotein goals in patients at high risk with severe hypercholesterolemia: efficacy and safety of ezetimibe co-administered with atorvastatin.
    Stein E; Stender S; Mata P; Sager P; Ponsonnet D; Melani L; Lipka L; Suresh R; Maccubbin D; Veltri E;
    Am Heart J; 2004 Sep; 148(3):447-55. PubMed ID: 15389231
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics and pharmacodynamics of nifedipine in untreated and atorvastatin-treated hyperlipidemic rats.
    Eliot LA; Jamali F
    J Pharmacol Exp Ther; 1999 Oct; 291(1):188-93. PubMed ID: 10490903
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The dual peroxisome proliferator-activated receptor alpha/gamma agonist tesaglitazar further improves the lipid profile in dyslipidemic subjects treated with atorvastatin.
    Tonstad S; Retterstøl K; Ose L; Ohman KP; Lindberg MB; Svensson M
    Metabolism; 2007 Sep; 56(9):1285-92. PubMed ID: 17697874
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessment of the efficacy and tolerability of a fixed dose combination of atorvastatin 10 mg + metformin SR 500 mg in diabetic dyslipidaemia in adult Indian patients.
    Balasubramanian R; Varadharajan S; Kathale A; Nagraj LM; Periyandavar I; Nayak UP; Sharma A; Bolmall C; Baliga VP
    J Indian Med Assoc; 2008 Jul; 106(7):464-7. PubMed ID: 18975505
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.